Neurosearch skyrockets on positive Phase III Huntington's results
This article was originally published in Scrip
Executive Summary
Neurosearch's novel therapy Huntexil (pridopidine) met its primary endpoint, improving motor function in a Phase III Huntington's study, show top-line results. Excited investors drove the share price up by over 100% to close at 168.00 Danish crowns ($31.55) on February 3rd on the Copenhagen Stock Exchange.